2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Tuesday, November 15, 2016

9:00AM-11:00AM: Abstract Number: 2363

Synovial Changes Detected By Ultrasound and Its Association with Knee Pain: A Population-Based Case Control Study

Osteoarthritis – Clinical Aspects - Poster II

9:00AM-11:00AM: Abstract Number: 2110

Synovial Fibroblasts Regulate B Cell Survival Via B Cell Activating Factor of the TNF Family (BAFF)

B Cell Biology and Targets in Autoimmune Disease - Poster II: Rheumatoid Arthritis and Other Rheumatic Diseases

9:00AM-11:00AM: Abstract Number: 2945

Systematic Review: “Efficacy and Safety of Biological Versus Immunosuppressive Therapy Compared to Placebo in the Treatment of Uveitis Associated with BehçEt’s Disease.”

Vasculitis - Poster III: Rarer Vasculitides

9:00AM-11:00AM: Abstract Number: 2849

Systemic Lupus Erythematosus Patients with Antibodies Against U1-Ribonucleoprotein Exhibit a Specific Pattern of Disease Manifestations

Systemic Lupus Erythematosus – Clinical Aspects and Treatment - Poster III: Biomarkers and Nephritis

9:00AM-11:00AM: Abstract Number: 2923

T-Cell Receptor Signaling Inhibition By CC-90005, a Selective Protein Kinase C Theta Antagonist, Reduces Antigen Mediated T-Cell Activation and Arthritis Pathology in the Mouse CIA Model

T Cell Biology and Targets in Autoimmune Disease - Poster Session II

9:00AM-11:00AM: Abstract Number: 2222

Tai Chi Is More Effective Than Aerobic Exercise in Treating Fibromyalgia: A Randomized Controlled Trial

Fibromyalgia, Soft Tissue Disorders, Regional and Specific Clinical Pain Syndromes - Poster II: Clinical Focus

9:00AM-11:00AM: Abstract Number: 2702

Taking Fly for Understanding the Molecular Role of HLA-B27/hB2m in Spondyloarthritis

Spondylarthropathies Psoriatic Arthritis – Pathogenesis, Etiology - Poster II

9:00AM-11:00AM: Abstract Number: 2791

Targeting Micro-RNAs Derived from Extracellular Vesicles to Inhibit of TLR7 and TLR8 Signaling Suppresses Inflammation in a Novel Human-Mouse Chimeric Model of Systemic Lupus Erythematosus

Systemic Lupus Erythematosus – Animal Models - Poster II

9:00AM-11:00AM: Abstract Number: 2107

Targeting Mir-155 in Rheumatoid Arthritis B Cells Reduces Antibody Production

B Cell Biology and Targets in Autoimmune Disease - Poster II: Rheumatoid Arthritis and Other Rheumatic Diseases

9:00AM-11:00AM: Abstract Number: 2599

TCZ Improves the Pro-Atherothrombotic Profile of Rheumatoid Arthritis Patients Modulating Endothelial Dysfunction, Netosis and Inflammation

Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy - Poster III

9:00AM-11:00AM: Abstract Number: 2498

Tender Joints Is a Consistent Negative Predictor of Sustained Remission in Aggressively Treated Patients with Early Rheumatoid Arthritis

Rheumatoid Arthritis – Clinical Aspects - Poster III: Treatment – Monitoring, Outcomes, Adverse Events

9:00AM-11:00AM: Abstract Number: 2141

Terminal Uridylyl Transferase ZCCHC6-Dependent Generation of miRNA Diversity in Primary Human Chondrocytes

Biology and Pathology of Bone and Joint - Poster I

9:00AM-11:00AM: Abstract Number: 2924

Terminally Differentiated CD8 T Cell Subset Has Distinct Signiture in RA

T Cell Biology and Targets in Autoimmune Disease - Poster Session II

9:00AM-11:00AM: Abstract Number: 2248

The “Financial Toxicity” of Therapy in Patients with Rheumatoid Arthritis

Health Services Research - Poster III

9:00AM-11:00AM: Abstract Number: 2101

the Association Between ABO Blood Types and Venous Thromboembolism in Individuals with a Positive Antiphospholipid Antibody Profile Is Varied By Sex

Antiphospholipid Syndrome - Poster II

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].